The acquisition is immediately accretive and extends Collegium's revenue runway with long patent protection. Watch for integration execution and prescription trends for AZSTARYS in upcoming quarters. The $300 million term loan increases leverage, but guided EBITDA of $475-$500 million provides strong coverage. Leadership departures are notable but appear orderly.
COLL drugs
COLL drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $35.69entry
- T+1 · 6mo ago −2.30%α −2.87% · $34.87
- T+5 · 6mo ago −5.72%α −5.79% · $33.65
- T+20 · 5mo ago −2.49%α −0.77% · $34.80
- T+60 · 3mo ago −18.44%α −22.82% · $29.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Collegium Pharmaceutical completed the acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for $650 million in cash, funded by existing cash and a new term loan. The company raised its 2026 guidance to reflect the deal, now expecting product revenues of $865-$895 million and adjusted EBITDA of $475-$500 million. The acquisition is expected to be immediately accretive and extends Collegium's revenue outlook with patent protection through 2037.
Key Financial Metrics
Key Facts
- Acquired AZSTARYS for $650 million in cash, funded by $350 million cash on hand and $300 million from a delayed draw term loan.
- Up to $135 million in additional milestone payments possible.
- AZSTARYS generated over 760,000 prescriptions in 2025; expected to contribute $60-$70 million in net revenue in H2 2026.
- 2026 guidance raised: product revenues $865-$895 million (from $805-$825 million); adjusted EBITDA $475-$500 million (from $455-$475 million).
- Annual run-rate synergies expected to exceed $50 million within 12 months.
- AZSTARYS has six Orange Book-listed patents, most expiring December 2037.
- Two leadership departures: CCO Scott Dreyer (end of August 2026) and CMO Thomas Smith (transition period).
Financial Impact
$650 million upfront cash acquisition, plus up to $135 million in milestones; 2026 revenue guidance raised by $60-$70 million; EBITDA guidance raised by $20-$25 million.
Risk Factors
- Integration risk: realizing $50 million+ synergies within 12 months may be challenging.
- Increased leverage from $300 million term loan; debt service costs could pressure margins.
- AZSTARYS revenue guidance of $60-$70 million for H2 2026 may be optimistic if prescription growth slows.
- Leadership departures of CCO and CMO could disrupt commercial and medical strategy.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292727 |
Track record
24 reports on COLL
1 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +0.28% at T+1 after the Aug 13, 2026 report. 1 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
- Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
- Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers